Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

3Shape settles Legal disputes with Align Technology

Copenhagen, February 7, 2022 - 3Shape, a global leader in digital solutions for dentistry, and Align Technology, Inc. have settled the ongoing patent infringement and antitrust legal disputes between the two companies. The terms of the settlement are confidential. Following the settlement, Align will continue its current practice of accepting scans from 3Shape TRIOS 2 and 3Shape TRIOS 3 intraoral scanners in certain jurisdictions outside the United States. Jakob Just-Bomholt, CEO of 3Shape, commented, "I am pleased that we have reached a fair and equitable agreement with Align

M Bilar Group increases heavily their marketing commitment to 3,615,000 SEK with Ampilio for 2022

M Bilar Group increases heavily their marketing commitment to 3,615,000 SEK with Ampilio, a subsidiary of SpectrumOne, for 2022 - a significant increase of over 110% compared to last year's contract.   M Bilar Group sells and serves BMW and MINI, and is one of Sweden's largest BMW dealers in Sweden. They have facilities in Eskilstuna, Västerås, Örebro, and Borlänge. Their earnings development has been through a great trend during the years they have been working with Ampilio. The company has sales reaching approximately SEK 1,4 Billion annually and is seeing an unbroken trend of higher

BioStock: Cyxone about the advancements in the T20K project

Biotech company Cyxone recently announced the next step in the T20K project, their drug candidate for multiple sclerosis. The company has signed an agreement with a renowned European contract development and manufacturing organisation for the scale up and manufacturing of the active ingredient of T20K. BioStock reached out to Cyxone’s CEO Tara Heitner for a comment.Read the interview with Cyxone's CEO Tara Heitner at biostock.se: https://www.biostock.se/en/2022/02/cyxone-on-the-advancements-in-the-t20k-project/ This is a press release from BioStock - Connecting Innovation & Capital.

Students assist in appeal to identify possible murder victim

A fresh appeal to identify a suspected murder victim found nearly three decades ago has launched thanks to new leads uncovered by Staffordshire University students.On 11 July 1994, the body of a middle-aged man believed to be British was recovered by a police boat in the North Sea, West of the Island Heligoland near Germany. The body showed injuries on the head and upper body, and there was evidence of him having been weighted down, suggesting intentional harm. Previous attempts to identify the man dubbed ‘the gentleman’ by German police have been unsuccessful and the case remains open.

Top-class young mathematics researchers recruited to Sweden

Knut and Alice Wallenberg Foundation has allocated SEK 50 million for recruitment of four pre-eminent mathematics researchers to three Swedish universities.“In the prevailing global situation and thanks to the Foundation’s ongoing major mathematics initiative, Sweden has become attractive to leading researchers in mathematics. Combined with the general increasing competitiveness of Swedish mathematics, this has created the potential to recruit top-class researchers to Sweden, making a significant contribution to the development of Swedish research” says Peter Wallenberg Jr, Chair of Knut

Invitation to teleconference/audio transmission

Concordia Maritime welcomes you to participate in a teleconference/audio transmission on February 10, 2022 at 3.00 pm CET.The session will feature a presentation of the Financial Statement for the full year 2021 and a Q&A session. Presiding: Erik Lewenhaupt, CEOMartin Nerfeldt, CFO The teleconference will be available at: SE: +46856642692UK: +443333009265US: +16467224902 To access the audio transmission, please click on the link below: https://tv.streamfabriken.com/concordia-maritime-q4-2021 Questions can be posed verbally via the teleconference, or in writing via

Redwood Pharma receives approval from an Austrian ethics committee for start of a clinical trial of RP501

Redwood Pharma has received approval from an Austrian ethics committee for the start of a clinical trial of RP501. This application represents the first of two necessary approvals for the commencement of the clinical trial. The company will now submit the clinical trial application for national approval by the Austrian Federal Office for Safety in Health Care (BASG). This initiates Redwood Pharma’s development efforts towards a CE-marking approval of RP501, the company’s novel, first-line treatment for relief of dry eye disease (DED). A CE-marking approval will facilitate the future sale of

61 percent of Inwido's sales 2021 met the Taxonomy's screening criteria

When Inwido sums up the 2021 sales of windows and doors via the Group's 29 business units, 61 percent of the sales reach the screening criteria in the taxonomy to make a substantial contribution, which are stated at a u-value of 1.0 for windows and 1.2 for doors. The share is a significant step forward compared to a share of 45 percent for the 2020 financial year.The European Commission's limit values aim to steer investments towards the use of modern windows and doors, which are significantly more energy-saving than older products that are to a very large extent found in today's buildings

SAS Traffic figures - January 2022

Ramp-up was slowed down by Omicron in JanuaryIn January 760,000 passengers traveled with SAS, an increase of 170% compared to the same month last year. SAS’ capacity also increased by approximately 170% compared with the same period last year. In comparison with last month, the total number of passengers decreased with almost 25% and capacity was reduced by almost 10%. The flown load factor for January was 49%, an improvement of 19 percentage points compared to January last year. “It will come as no surprise that Omicron had an impact on customer demand during the month, with additional

Webcast with Teleconference, Q4 / 2021

Nitro Games to host a Webcast with Teleconference on Monday 14 February 2022 09:30 Swedish time.Nitro Games Oyj Year-End Report for January - December 2021 will be released on Monday 14 February 2022. The Company will do a presentation after the release of the report. Participants can join this presentation by a Webcast or Teleconference. Participants can send questions to the presenters via email below. 14 February 2022 09:30 (Europe/Stockholm) Details of event: https://financialhearings.com/event/13859 Language: English Activity: Webcast with Teleconference Webcast: https://

ContextVision confirms the value of the upcoming dividend

Stockholm, February 7[th], 2022, in accordance with the regulations of the Oslo Stock Exchange. ContextVision hereby confirms the value of the upcoming dividend. In accordance with the information in the notice to the Extraordinary General Meeting published on November 15, 2021, the company confirms that the value of the dividend distribution in form of the shares in Inify Laboratories AB is equal to the book value of the relevant assets in ContextVision and amounts to SEK 31,753,090. This represents a distribution of SEK 0.41 per share held in ContextVision. https://www.

OssDsign steps up ambition to generate further clinical evidence for its bone replacement products through key recruitment

Uppsala, February 7, 2022. OssDsign AB (publ.) today announces that Melanie Marshall has been recruited to a new position as Vice President Clinical & Medical Affairs. This is an important step in the strategic ambition to accelerate data collection and publication of clinical evidence for the company’s innovative bone replacement products, OssDsign Cranial PSI and OssDsign Catalyst. Melanie Marshall has a wealth of experience from senior positions at global medtech companies, such as Boston Scientific, Apatech/Baxter and Medtronic.The creation of a new senior position with responsibility

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 33 - 7 FEBRUARY 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 75/2021. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tel.: 3315 0451

DAMPSKIBSSELSKABET NORDEN A/S – WEEKLY REPORT ON SHARE BUY-BACK

ANNOUNCEMENT NO. 32 - 7 FEBRUARY 2022 On 4 November 2021, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 4 November 2021 up to and including no later than end February 2022. For details, please see announcement no. 75 of 4 November 2021. Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 40 million (approximately DKK 263 million).

Valmet to supply quality control system to Papeterie Le Bourray in France

Valmet Oyj’s trade press release on February 7, 2022 at 11.00 EETValmet will supply IQ Quality Control System to Papeterie Le Bourray in France. The new system will replace the aging old third-party system and will be installed on tissue machine TM 3 at the company’s mill in Saint-Mars-La-Brière, North West France. The target is to optimize production and improve the end-product quality. The order was included in Valmet’s orders received of the fourth quarter 2021. The delivery will take place in November 2022. This is the second Valmet IQ Quality Control system order to Papeterie Le

LET’S GET IT ON: ‘Marvin Gaye’ serenades endangered monkeys in Trentham during mating season

This week, monkeys at Trentham Monkey Forest were treated to a live performance from love song legend Marvin Gaye to help boost the monkey love this mating season.Trentham Monkey Forest is home to 140 free roaming Barbary macaques, a tail-less species of monkey that originate from Algeria and Morocco. As every new addition is so important for the protection of the species, special guest Dave Largie was invited in to serenade the primates, with the most well-known love songs of all time, to help inspire them to ‘get it on’. David, a highly experienced love song guru, sang several

Glaston publishes the 2021 Financial Statements Bulletin on February 14, 2022, at 13.00 p.m.

Glaston Corporation    Press release                  7.2.2022 at 11.00Glaston Corporation will publish its January−December 2021 Financial Statements Bulletin on Monday, 14 February 2022 at around 13.00 p.m. Finnish time. The Financial Statements Bulletin and presentation will be available as soon as possible after publishing on the Company’s internet pages at www.glaston.net.Glaston’s President and CEO Anders Dahlblom and CFO Päivi Lindqvist will present the financial result to analysts, investors and media representatives on the same day at 15.00 (Finnish time) in English. The live

Invitation to Fractal Gaming Group’s Year-end report, Q4 2021

Fractal Gaming Group AB will publish its Year-end report, Q4 on Thursday, February 10, 2022 at 08.00 (CET). In conjunction to this, a telephone and web conference will be organized for investors, analysts and media on the same day at 09.00 (CET). CEO, Hannes Wallin and CFO, Karin Ingemarson will present and comment on the report and the conference followed by a question and answer session.To attend the telephone or web conference:SE: +46856642706UK: +443333009032US: +16319131422  Link to web conference:https://tv.streamfabriken.com/fractal-gaming-group-q4-2021  For more

Devyser acquires Italian SmartSeq and strengthens position in genetic data analysis

Stockholm, February 7, 2022 – Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announced that the company has utilized an option to acquire all of the remaining shares in the associated company SmartSeq S.r.l. (“SmartSeq”). The acquisition corresponds to 70% of shares in SmartSeq and the purchase consideration amounts to EUR 835,000, of which 29% in cash and 71% in newly issued Devyser shares. The acquisition strengthens Devyser’s customer offering for diagnostic analysis and is expected to have a positive impact on Devyser’s gross profit and gross margin. In

UK food companies choose DUG for vegetarian and vegan products

Veg of Lund has started selling its plant-based drink DUG directly to food manufacturers in the UK. This category consists of convenience food suppliers, beverage manufacturers and developers of new dishes, that complements Veg of Lund’s existing customer categories.The launch of Veg of Lund’s DUG[®] plant-based drink in the UK has been primarily through supermarkets and cafés. In a short period of time, DUG has gained consumer appreciation and several media outlets have given the drink high ratings in tests of the range of plant-based products. As the UK business sector reboots in 2022

Shareholder Letter and Invitation to webcast Presentation

Oslo, February 7, 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), a Nordic-based medtech company focused on developing and commercializing proprietary and innovative medtech products to the global market through organic growth and targeted M&A, today publishes a shareholder letter (in Norwegian) in relation to the fully underwritten rights issue in the Company (the "Rights Issue"). The Rights Issue was approved at the Company's extraordinary general meeting, hosted Friday, February 4, 2022. The letter to our shareholders is enclosed to this release. The

DBP International AB: a new patent for SA-033 is granted in Japan

Double Bond Pharmaceutical's forth patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the basis for the BeloGal® technology platform has been granted in Japan. Patent approval provides protection for the treatment method and the design of composition for DBP's front-line product SA-033. "We are very pleased because it is an important milestone in the development of balanced product pipeline", - comments Igor Lokot, CEO of DBP. More about SA-033: SA-033 is the first drug candidate that DBP has developed using its innovative drug

There are no items matching the current filter
There are no more items matching the current filter
Back to top